---
title: "Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised[comma] controlled[comma] open-label[comma] phase 3b trial."
date: 2022-04-29
enddate:
---

Published in: *The Lancet. Neurology*

DOI: [10.1016/S1474-4422(22)00143-0](https://doi.org/10.1016/S1474-4422(22)00143-0)

<img src="https://upload.wikimedia.org/wikipedia/commons/thumb/0/0e/Closed_Access_logo_transparent.svg/1200px-Closed_Access_logo_transparent.svg.png" alt="drawing" width="25" align="left"/> &nbsp;&nbsp;&nbsp;This publication is not available in Open Access.


